Invasive Breast Carcinoma

About
Mappings

OncoTree: Invasive Breast Carcinoma (oncotree:BRCA)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive Invasive Breast Carcinoma Fulvestrant
FDA (1) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
FDA (1) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine
FDA (1) HER2-positive Invasive Breast Carcinoma Neratinib
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
FDA (2) HC (2) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
FDA (2) HC (2) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
FDA (1) HC (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
FDA (2) HC (5) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (1) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab
FDA (1) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) HC (1) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (1) HC (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (1) HC (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
HC (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
HC (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
HC (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant
HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
HC (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Paclitaxel, Trastuzumab
FDA (1) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant
FDA (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan